Safety of Tralokinumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-blind, Placebo-controlled Phase 2 and Phase 3 Trials. - Université de Lille Accéder directement au contenu
Article Dans Une Revue The British journal of dermatology Année : 2022

Safety of Tralokinumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-blind, Placebo-controlled Phase 2 and Phase 3 Trials.

Résumé

Tralokinumab, an anti‐interleukin‐13 biologic for the treatment of atopic dermatitis (AD), has provided significant and early improvements in signs and extent of AD in key Phase 3 clinical trials and was well tolerated, with a safety profile comparable to placebo. This study comprehensively assessed the safety profile of tralokinumab using data from five placebo‐controlled trials in adult patients with moderate‐to‐severe AD, finding that overall incidence and rate of adverse events (AEs) was similar between tralokinumab and placebo in the initial treatment period (16 weeks) and did not increase over 52 weeks of continued treatment. Common AEs occurring more frequently with tralokinumab included conjunctivitis and injection site reaction.
Fichier principal
Vignette du fichier
bjd0888.pdf (618.46 Ko) Télécharger le fichier
Origine : Publication financée par une institution
Licence : CC BY NC - Paternité - Pas d'utilisation commerciale

Dates et versions

hal-04428303 , version 1 (14-02-2024)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Eric L. Simpson, Joseph F. Merola, Jonathan I. Silverberg, Kristian Reich, Richard B. Warren, et al.. Safety of Tralokinumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-blind, Placebo-controlled Phase 2 and Phase 3 Trials.. The British journal of dermatology, 2022, British Journal of Dermatology, 187, pp.888-899. ⟨10.1111/bjd.21867⟩. ⟨hal-04428303⟩

Collections

RIIP UNIV-LILLE
4 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More